Under the terms of the deal, 23andMe will acquire Lemonaid for $100 million in cash and $300 million in common stock. The transaction is expected to close by the end of the year.
Under the terms of the deal, 23andMe will acquire Lemonaid for $100 million in cash and $300 million in common stock. The transaction is expected to close by the end of the year.
Copyright © 2024 | WordPress Theme by MH Themes